SCM
TARS icon

Soleus Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Soleus Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-250,000
Closed -$4.44M – 101
2023
Q3 		$4.44M Buy
+250,000
New +$4.42M 0.41% 59

Other funds holding TARS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Soleus Capital Management's TARS Position: Q4 2023 in Review

Soleus Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q4 2023, closing a stake of 250,000 shares — an estimated $4.44M sold.

Soleus Capital Management first reported a position in TARS in Q3 2023 and held it in 1 quarter. The position peaked at $4.44M in Q3 2023. 116 funds tracked by Wall St. Rank hold TARS as of Q4 2023.

  • Soleus Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 250,000 Tarsus Pharmaceuticals shares in Q4 2023, an estimated $4.44M.
  • Soleus Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Soleus Capital Management's Tarsus Pharmaceuticals position peaked at $4.44M in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.